Michelle Dawson posts

Post published on Twitter/X on 3 Oct 2022 04:48

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post Question asked by Dawson in the post External link integrated into the post Autism terms
Open original post

1 integrated reply by Michelle Dawson

3 Oct 2022 04:53

Note: that makes 3 very similar (except for the drug being tested) trial registrations so far--for anyone keeping track, here are the other 2
https://t.co/Ik9CODwtB4
&
https://t.co/tGjb98LqQt

View reply on Twitter/X

Information about the link integrated into the post

Clinical trial

Stanford University, National Institutes of Health (NIH) (2023). Trial of Suvorexant for Sleep in Children With Autism. ClinicalTrials.gov. Stanford University.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Stanford University, National Institutes of Health (NIH) (2023). Trial of Suvorexant for Sleep in Children With Autism. ClinicalTrials.gov. Stanford University.

Publication date
9 Aug 2023
Identifier
NCT05546554
Authors
Stanford University, National Institutes of Health (NIH)
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Stanford University
Metadata source
clinicaltrials.gov

Abstract

The purpose of this study is to examine the effect of suvorexant on sleep in children and adolescents with Autism Spectrum Disorder (ASD). Suvorexant is a selective, dual orexin receptor antagonist (DORA) used for the treatment of sleep onset difficulties and/or sleep maintenance. To accomplish this, the investigators will use a randomized double-blind placebo-controlled crossover 8-week study design to examine the effect of suvorexant on sleep physiology as assessed by polysomnography (PSG), actigraphy, circadian rhythm, and clinical measures.

Open source